Biota Holdings Limited engages in the drug discovery and clinical development of anti-infectives in Australia. It specializes in respiratory diseases, primarily influenza. The company offers zanamivir, a neuraminidase inhibitor for the treatment and prevention of influenza, which it markets under the Relenza brand name through a licensing agreement with GlaxoSmithKline. It also provides influenza diagnostics test kits, such as BioStar OIA FLU that detects influenza and assists the physician to differentiate influenza from other respiratory infections which may display similar symptoms; and Biostar OIA FLU A/B, a differentiated flu test. In addition, the company develops nucleoside analogues designed to treat hepatitis C virus infections, licensed to Boehringer Ingelheim; and a series of candidate drugs aimed at the treatment of respiratory syncytial virus disease. Further, it has clinical trials underway with its lead compound for human rhinovirus infection in patients with compromised respiration or immune systems. The company has a partnership with Daiichi Sankyo for the development of second generation influenza anti-virals or long acting neuraminidase inhibitors. The company was incorporated in 1985 and is based in Notting Hill, Australia.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for BTAHY